Healthcare
Genomma Lab Internacional, S.A.B. de C.V.(GNMLF)
Live Price
Offline$0.84
+0.00% today
1Y Change
-26.32%
Window
Jun 25, 2025 β Jun 19, 2026
- Market Cap
- $16.17B
- Revenue Growth
- +9.0%
- EPS Growth
- -94.0%
- Dividend Yield
- 4.8%
Coverage: 253 bars Β· Jun 25, 2025 β Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is a Healthcare stock with a market cap of $16.17B and listed on OTC. The stock last traded around $0.84 and down 26.3% across the available one-year price window (Jun 25, 2025 β Jun 19, 2026). Baseline metrics include revenue growth of +9.0%, EPS growth of -94.0%, a dividend yield of 4.8%. What stands out right now is revenue +9.0%, EPS -94.0%, free cash flow -51.7% with operating margin 21.2% and ROIC 14.4%. The dividend matters to the case here, with a current yield around 4.8%. Valuation is more restrained than many high-expectation growth names at P/E 9.7 and price/sales 0.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GNMLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+9.0% vs +7.6% peer median
Operating Margin
Near sector median
+21.2% vs +19.4% peer median
P/E
Below sector median
9.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +9.0% and EPS is at -94.0%, with operating margin around 21.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | β | +0.0% | +0.0% | +0.0% |
2026 Feb 25, 2026 | -17.9% | +0.0% | +0.0% | +0.0% |
2025 Oct 23, 2025 | -13.7% | +0.0% | +5.9% | +2.5% |
Benchmark Edge
GNMLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNMLF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNMLF Max Drawdown
-28.21%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GNMLF and SPY.
Company Overview
Genomma Lab Internacional, S.A.B. de C.V.
Other OTC
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, TΓo Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
- Leadership
- Juan Marco Sparvieri
- IPO Date
- May 4, 2012
- Employees
- 1.6k
- Street Address
- Av. Antonio DovalΓ Jaime no.70
- Mailing
- Mexico City, DF, 01210
- Region
- Mexico City, DF, MX
- Reporting Currency
- USD
- Investor Line
- 52 55 5081 0000
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.7
- EV/EBITDA
- 5.0
- Price/Sales
- 0.9
- Price/Book
- 1.4
Growth
- Revenue
- +9.0%
- EPS
- -94.0%
- Free Cash Flow
- -51.7%
Profitability
- Gross Margin
- 62.7%
- Operating Margin
- 21.2%
- Net Margin
- 9.6%
- ROE
- 14.8%
- ROIC
- 14.4%
Balance Sheet
- Debt/Equity
- 0.40
- Current Ratio
- 1.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.